Ludwig Institute for Cancer Research Limited

Katharina Fleischauer

Thierry R Boon-Falleur

Pierre Van Der Bruggen

Catia Traversari

Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These &ldquo;T-RAS&rdquo; bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.

Method for stimulating CTLs with peptides

Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These 'TRAS' bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.

Growing community of inventors

Milan, Italy

Katharina Fleischauer